LansoprazoleThird Party Manufacturing in India

Lansoprazole suppresses gastric acid secretion by irreversibly inhibiting the hydrogen-potassium adenosine triphosphatase (H⁺/K⁺ ATPase) enzyme system, commonly known as the proton pump, located on the secretory surface of gastric parietal cells. As a substituted benzimidazole prodrug, Lansoprazole is a weak base that accumulates in the acidic environment of the parietal cell canaliculus, where it undergoes protonation and conversion to its active sulphenamide form. This active species forms covalent disulphide bonds with cysteine residues on the alpha subunit of the H⁺/K⁺ ATPase enzyme, permanently inactivating the proton pump. Acid secretion resumes only after new proton pumps are synthesised and inserted into the membrane, typically over 24-48 hours. Lansoprazole is more potent than omeprazole on a milligram basis and has a faster onset of action due to its higher pKa, which enables more rapid accumulation in the parietal cell. The drug provides consistent 24-hour acid suppression with once-daily dosing and shows minimal food interaction, allowing flexible administration. Its anti-secretory effect also suppresses Helicobacter pylori growth indirectly, contributing to its role in eradication regimens.

Therapeutic Uses

Lansoprazole is prescribed for the treatment of:

• Gastroesophageal Reflux Disease (GERD): Healing erosive oesophagitis and providing long-term maintenance therapy.
• Peptic Ulcer Disease: For gastric and duodenal ulcers, including NSAID-induced ulcer prophylaxis and treatment.
• Helicobacter pylori Eradication: As part of triple therapy regimens with amoxicillin and clarithromycin, or metronidazole and tetracycline.
• Zollinger-Ellison Syndrome: Managing gastric acid hypersecretion in patients with gastrinoma.
• Functional Dyspepsia: Symptomatic relief in patients with epigastric pain or burning without organic pathology.
• Stress Ulcer Prophylaxis: In critically ill patients to reduce upper gastrointestinal bleeding risk.

Why Manufacturers Choose Lansoprazole

Lansoprazole is one of the most widely prescribed proton pump inhibitors globally, with established generic markets across India, the US, Europe, and Latin America. The molecule offers manufacturing flexibility, with delayed-release capsules, orally disintegrating tablets, and sachet/pellet formulations, each serving distinct patient populations and price points. Indian manufacturers have deep expertise in PPI formulation, including enteric coating technologies required for delayed-release products. The API supply chain for Lansoprazole is mature and cost-competitive, with multiple Indian manufacturers producing high-quality material. The pellet-based sachet formulation represents a growing segment in paediatric and elderly care, offering differentiation opportunities for contract manufacturers.

This makes Lansoprazole one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.